Recent Updates
Recently added Catalysts
OGI Neutral Sentiment Score: 60/100

Organigram Announces Interim Chief Financial Officer TORONTO--(BUSINESS WIRE)

Key Takeaway: Organigram Holdings Inc. has announced that Derrick West will transition away from his role as Chief Financial Officer to focus on health recovery following surgery. In his place, Paolo De Luca, who previously served as CFO from 2017 to 2020, has been appointed as interim CFO effective November 13, 2023. The Board has expressed gratitude for West's contributions during his tenure, noting his role in stabilizing financial processes and supporting company growth. The company is currently searching for a permanent CFO to fill the position long-term.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Paolo De Luca as interim CFO indicates leadership stability.
  • Derrick West's contributions to the company acknowledged positively.
  • Prior experience of Paolo De Luca as CFO brings familiarity and potential continuity.

CONCERNS & RISKS

  • Derrick West's transition from the CFO role due to health concerns.
  • Potential risks in the search process for a new permanent CFO.

Full Press Release Details

Organigram Announces Interim Chief Financial Officer

TORONTO--(BUSINESS WIRE)--November 10, 2023--The Board of Directors (the "Board") of Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI) (NASDAQ: OGI) today announced that Derrick West has informed Organigram that
he will transition away from his role as Chief Financial Officer ("CFO") in order to take time to focus on his health and recovery following surgery later this month.
Paolo De Luca, current Chief Strategy Officer, has been appointed interim CFO effective November 13, 2023, while the Company completes a search for a new permanent CFO. Paolo previously served as the Company's CFO between 2017 and 2020.
"Derrick has left a legacy of stabilizing our financial processes along with the implementation of our ERP and has supported the Company through a period of high growth including the acquisitions of our Winnipeg and Lac-Sup rieur facilities,"
said Ms. Goldenberg, CEO of Organigram. "We are grateful for his contributions during his time on the board beginning in 2017 and since becoming CFO in 2020 and we wish him well."
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc. a licensed producer of cannabis, cannabis-derived products and cannabis infused edibles in Canada.
Organigram is focused on producing high-quality cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend its global footprint. Organigram has also developed and acquired a
portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and
Lac-Sup rieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of
such words and phrases or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, and include statements regarding the search process and anticipated skill set for a permanent
CFO. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future
results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Such risks include the risk that Organigram may not be able to identify or attract candidates having the desired skill
set as permanent CFO on a timely basis or at all, and the factors and risks as disclosed in the Company's most recent annual information form, management's discussion and analysis and other Company documents filed from time to time on SEDAR
(see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking information included in
this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new
information, future events or otherwise.

Contacts

Paolo DeLuca, Chief Strategy Officer

Frequently Asked Questions

Who is the new interim CFO of Organigram?

Paolo De Luca has been appointed as the interim CFO effective November 13, 2023.

Why is Derrick West leaving his CFO role?

Derrick West is transitioning from his role to focus on his health following surgery.

When did Paolo De Luca previously serve as CFO?

Paolo De Luca served as CFO from 2017 to 2020 at Organigram.

What products does Organigram produce?

Organigram produces cannabis, cannabis-derived products, and cannabis-infused edibles.

What is Organigram's focus in the market?

The company focuses on high-quality cannabis for patients and adult recreational users.

Last updated: Nov 10, 2023